Eli Lilly and Co
Novavax shares jump after Covid vaccine maker posts surprise quarterly profit
Medical syringes and Novavax logo displayed in the background are seen in this illustration photo taken in Krakow, Poland on December 2, 2021. Jakub Porzycki | NurPhoto | Getty Images Shares of Novavax jumped as much as 20% in premarket trading Tuesday after the Covid vaccine maker reported a surprise second-quarter profit. The results come […]
Read More
Eli Lilly raises full-year guidance as drug pipeline drives second-quarter profit up 85%
Sopa Images | Lightrocket | Getty Images Eli Lilly on Tuesday raised its full-year guidance as second-quarter profit jumped 85% from the same period a year ago on strong sales from the pharmaceutical giant’s drug pipeline. The company now expects full-year revenue of between $33.4 billion to $33.9 billion, up from a previous forecast of […]
Read More
Here are the 5 price-target changes and 4 trades we made during this busy earnings week
In a jam-packed week of earnings, the Club executed multiple trades and elevated price targets for some of our biggest stocks. Many of these moves stemmed from what we saw in quarterly numbers and heard on conference calls. Here’s a day-by-day look at the portfolio action. Monday The week began with our decision to exit […]
Read More
Inflation requires heart phase in the 7 days forward as Wall Avenue appears to be for a lot more clues on Fed level hikes
New inflation knowledge set for launch in the 7 days in advance could assistance Wall Road regain its footing. The most recent browse on the consumer price tag index — an inflation gauge that steps what consumers pay out for a numerous products — is thanks out Thursday. The July producer value index — which […]
Read More
These health-care companies see opportunity ahead from Alzheimer’s drug approval
As patients with Alzheimer’s disease seek out a newly approved treatment, they will need MRIs, blood tests and other diagnostics, fueling increased demand for these important tools. In earnings calls this week, both GE Healthcare and Quest Diagnostics made references to the potential opportunity here, although neither company put any specific estimates behind their comments. […]
Read More
This under-the-radar biotech could be the next way to play the obesity drug boom
The lucrative market for obesity drugs is dominated by two players right now, but Structure Therapeutics has the potential to enter the category with an oral GLP-1 medication, according to Piper Sandler. Analyst Yasmeen Rahimi initiated coverage of the clinical stage drugmaker with an overweight rating on Thursday, and set a $58 price target, which […]
Read More
Eli Lilly says obesity drug helped boost weight loss to 26%, highest seen in late-stage trials
The Eli Lilly logo is shown on one of the company’s offices in San Diego, California, September 17, 2020. Mike Blake | Reuters An Eli Lilly experimental drug helped patients lose about 26% of their weight on average following extended use or intensive lifestyle changes, according to results from two studies released Thursday. It’s the […]
Read More
UK investigates weight loss, diabetes drugs like Wegovy and Ozempic for suicide risks
Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy. Stefan Trumpf | Picture Alliance | Getty Images U.K. health authorities on Wednesday said they are reviewing obesity and diabetes drugs like Novo Nordisk‘s Wegovy and Ozempic after some patients who took the treatments […]
Read More
Weight loss drug Wegovy is from Europe — but users in the region face a long and costly wait
Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy. Stefan Trumpf | Picture Alliance | Getty Images Danish pharmaceutical giant Novo Nordisk is set to launch its hugely popular Wegovy obesity drug in Germany this month, but it could be some time before […]
Read More
Morgan Stanley sees profound shift in diabetes treatment boosting opportunity for weight-loss drugs
Morgan Stanley analysts said they are seeing a profound shift in the way diabetes is being treated, with doctors intensifying the focus on weight management, which is accelerating the uptake of GLP-1 medications. What’s more, the analysts anticipate that over the next 24 months, this weight-centric approach will start to spread to other health complications […]
Read More